Eurofins to Acquire ViraCor-IBT Laboratories - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eurofins to Acquire ViraCor-IBT Laboratories



Eurofins Scientific has signed a definitive agreement to acquire ViraCor-IBT Laboratories, a provider of specialty diagnostic testing, including biologic and molecular testing, from majority owner Ampersand Capital and other shareholders for approximately $255 million, subject to post-closing adjustments.

Eurofins reports that the acquisition will strengthen both its pharmaceutical and genomic service offerings and establish a presence in the specialty clinical testing services for infectious disease, immunology, allergy, HLA, and serology. The transaction also includes retaining VIBT’s 270 employees.

Upon closing of the transaction the company will continue to be known as ViraCor-IBT Laboratories. Completion of the transaction is expected in the next 60 days.

Source: Eurofins Scientific

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here